表紙
市場調查報告書

癌症免疫治療全球市場:按類型 (單株抗體 (非修飾、複合型)、癌症疫苗、免疫檢查點抑制劑 (PD-1、PD-L1、CTLA-4))、按應用 (肺癌、黑色素瘤、白血病、淋巴瘤) 的未來預測 (2022年前)

Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 923466
出版日期 內容資訊 英文 230 Pages
訂單完成後即時交付
價格
癌症免疫治療全球市場:按類型 (單株抗體 (非修飾、複合型)、癌症疫苗、免疫檢查點抑制劑 (PD-1、PD-L1、CTLA-4))、按應用 (肺癌、黑色素瘤、白血病、淋巴瘤) 的未來預測 (2022年前) Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022
出版日期: 2020年01月01日內容資訊: 英文 230 Pages
簡介

預估全球癌症免疫治療將於2022年超過1000億美元規模。按類型分類中,單株抗體 (mAb) 占最大占比;區域方面由北美各國掌握市場主導權。

本報告研究全球癌症免疫治療市場,彙整疾病概要與主要治療方法、市場基本結構與主要市場推動阻礙因素、市場規模實績和預測 (過去2年和未來4年),提供按類型、應用、地區的詳細動向,以及資本交易和業務發展動向、主要企業簡介等情報。

第1章 分析師見解

第2章 研究方法

第3章 癌症免疫治療:概要

第4章 市場動態

  • 市場推動因素
    • 癌症發病率上升
    • 免疫檢查點抑制劑銷售推動市場成長
    • 老年人口增加
    • 已開發國家的高額醫療費用
    • 強健的PIPELINE
    • 針對各種適應的療效提升
    • 癌症免疫治療核准和攝取激增
  • 課題
    • 暢銷藥品的專利到期
    • 免疫治療後的副作用增加
    • 癌症免疫治療的高昂開發成本
    • 高額的治療費用
    • 欠缺認知度
  • 市場機會
    • Opdivo和Keytruda的龐大成長機會
    • 併用療法:大幅提升生存率的可能性
    • CAR-T療法:癌症治療的未來
    • 小型企業為次世代型免疫治療提供了龐大市場機會

第5章 全球癌症免疫治療市場未來展望 (2022年)

第6章 全球癌症免疫治療市場:按產品級別

  • 單株抗體(mAbs)
    • 非修飾單株抗體
    • 複合型單株抗體
    • 雙特異性單株抗體
    • 其他
  • 治療疫苗
    • Provenge
  • 免疫檢查點抑制劑
    • CTLA-4抑制劑
    • PD-1/PD-L1抑制劑
  • 其他

第7章 癌症免疫治療全球市場:按主要症狀

  • 頭部/頸部癌症
  • 肺癌
  • 黑色素瘤
  • 淋巴瘤
  • 白血病
  • 其他

第8章 癌症免疫治療全球市場:按地區

  • 北美
  • 歐洲
  • 亞太地區

第9章 市場趨勢與發展

  • 有利可圖的投資動向
  • 標靶療法/併用療法的出現
  • NSCLC (非小細胞肺癌) 和黑色素瘤對癌症免疫治療市場貢獻最大
  • Bristol-Myers Squibb and Merck & Co:免疫腫瘤治療頂尖翹楚

第10章 癌症免疫治療產業的策略合作與聯盟

第11章 癌症免疫治療PIPELINE分析

第12章 競爭環境

  • 主要企業市場占比

第13章 主要企業分析

  • F. Hoffmann-La Roche AG
  • Celgene Corporation
  • ristol-Myers Squibb
  • Merck & Co., Inc.
  • Novartis
  • AstraZeneca Plc
  • Pfizer Inc
  • Eli Lilly and Company
  • Johnson & Johnson
  • Amgen Inc.
目錄

Immuno-oncology is a unique approach that uses the body's immune system to fight cancer. These therapies activate an individual's immune system, making it able to recognize cancer cells and destroy them. Immuno-oncology therapies provide long lasting anti-cancer benefits to patients who previously had very few treatment options available to them. These therapies work against a large number of cancer types. The technological advancements are helping the growth of immuno-oncology market. The biotechnology and pharmaceutical companies are striving to launch new and most effective therapies.

According to the report "Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022", the global immuno-oncology market is anticipated to cross US$ 100 Billion by 2022. The report provides a detailed analysis of the global immuno-oncology market. The report also provides the current and forecasted market for immuno-oncology.

Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immuno-oncology market. Moreover, the report provides the sales of major marketed immuno-oncology drugs.

The global immuno-oncology market has been segmented on the basis of type of product into monoclonal antibodies, therapeutic vaccines, and immune checkpoint inhibitors amongst others. According to the report, monoclonal antibodies segment was estimated to account for the largest share in 2016 due to rising prevalence of cancer & rising usage in a number of therapies (antibody-directed enzyme pro-drug therapy and radio immunotherapy).

The report also sheds light on the geographic segmentation of the global immuno-oncology market. In 2016, North America was estimated to account for the largest share. Presence of major players, increased awareness and better distribution mechanisms are some of the prominent factors that have led to North America being the market leader.

On the basis of type of cancer, the immuno-oncology market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immuno-oncology market. The report provides the market analysis of major indications along with the forecast till 2022.

A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immuno-oncology programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.

The later part of the report discusses some of the prominent players in the global immuno-oncology market. Market share analysis of major players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Overall, immuno-oncology is an important and rapidly emerging field. This report will prove as a complete source of knowledge and analysis for clients and potential investors.

1. Analyst View

2. Research Methodology

3. Immuno-Oncology: Overview

4. Market Dynamics

  • 4.1 Drivers
    • 4.1.1 Increasing Cancer Incidences
    • 4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth
    • 4.1.3 Growing Geriatric Population
    • 4.1.4 High Healthcare Spending in Developed Economies
    • 4.1.5 Strong Pipeline
    • 4.1.6 Increasing Efficacy in a Wide Variety of Indications
    • 4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products
  • 4.2 Challenges
    • 4.2.1 Patent Expiry of Top-Selling Drugs
    • 4.2.2 Increasing Number of Side-Effects Post Immunotherapy Treatment
    • 4.2.3 Sky-High Development Costs of Cancer Immunotherapies
    • 4.2.4 High Cost of Treatment
    • 4.2.5 Lack of Awarenes
  • 4.3 Opportunities
    • 4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity
    • 4.3.2 Combination Therapies Could Lead to Substantial Increase in Survival
    • 4.3.3 CAR-T Therapies: The Future of Cancer Care
    • 4.3.4 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies

5. Global Immuno-Oncology Market Outlook 2022

6. Global Immuno-Oncology Market, by Product Class

  • 6.1 Monoclonal Antibodies (mAbs)
    • 6.1.1 Naked Monoclonal Antibodies
      • 6.1.1.1 Rituxan (Rituximab)
      • 6.1.1.2 Avastin (Bevacizumab)
      • 6.1.1.3 Herceptin (Trastuzumab)
    • 6.1.2 Conjugated Monoclonal Antibodies
      • 6.1.2.1 ADCETRIS (Brentuximab vedotin)
      • 6.1.2.2 Kadcyla (Ado-trastuzumab emtansine/TDM-1)
    • 6.1.3 Bispecific Monoclonal Antibodies
      • 6.1.3.1 Blincyto (Blinatumomab)
    • 6.1.4 Others
  • 6.2 Therapeutic Vaccines
    • 6.2.1 Provenge
  • 6.3 Immune Checkpoint Inhibitors
    • 6.3.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)
      • 6.3.1.1 Yervoy (Ipilimumab)
    • 6.3.2 PD-1 and PD-L1 Inhibitors(Programmed Death-1 and Programmed Death-Ligand 1)
      • 6.3.2.1 Opdivo (Nivolumab)
      • 6.3.2.2 Keytruda (Pembrolizumab)
  • 6.4 Others

7. Global Immuno-Oncology Market, By Major Indications

  • 7.1 Head & Neck Cancer
  • 7.2 Lung Cancer
  • 7.3 Melanoma
  • 7.4 Lymphoma
  • 7.5 Leukemia
  • 7.6 Others

8. Global Immuno-Oncology Market, By Geography

  • 8.1 North America
  • 8.2 Europe
  • 8.3 Asia-Pacific

9. Trends & Developments

  • 9.1 Lucrative Investment Trends
  • 9.2 Emergence of Targeted and Combination Therapies
  • 9.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market
  • 9.4 Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers

10. Strategic Collaborations & Alliances in the Immuno-Oncology Industry

11. Pipeline Analysis of Immuno-Oncology

12. Competitive Landscape

  • 12.1 Share of Major Players

13. Key Players Analysis

  • 13.1 F. Hoffmann-La Roche AG
  • 13.2 Celgene Corporation
  • 13.3 Bristol-Myers Squibb
  • 13.4 Merck & Co., Inc.
  • 13.5 Novartis
  • 13.6 AstraZeneca Plc
  • 13.7 Pfizer Inc
  • 13.8 Eli Lilly and Company
  • 13.9 Johnson & Johnson
  • 13.10 Amgen Inc.

List of Figures:

  • Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
  • Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030
  • Figure 4-3: Global - Population above 60 Years (Billion), 2015 & 2050
  • Figure 4-4: Expected Combination Regimen Launches in Oncology
  • Figure 5-1: Global - Immuno-Oncology Market (Billion US$), 2016-2022
  • Figure 6-1: Global - Share of Immuno-Oncology Market by Product (%), 2016
  • Figure 6-2: Global - Share of Immuno-Oncology Market by Product (%), 2022
  • Figure 6-3: Global - Monoclonal Antibodies Market (Billion US$), 2016-2022
  • Figure 6-4: Global - Rituxan Market (Billion US$), 2012-2016
  • Figure 6-5: Global - Avastin Market (Billion US$), 2012-2016
  • Figure 6-6: Global - Herceptin Market (Billion US$), 2012-2016
  • Figure 6-7: Global - ADCETRIS Market (Million US$), 2012-2016
  • Figure 6-8: Global - Kadcyla Market (Million US$), 2013-2016
  • Figure 6-9: Global - Blincyto Market (Million US$), 2014-2016
  • Figure 6-10: Global - Other Monoclonal Antibodies Market (Billion US$), 2016-2022
  • Figure 6-11: Global - Therapeutic Cancer Vaccines Market (Billion US$), 2016-2022
  • Figure 6-12: Global - Provenge Market (Million US$), 2012-2016
  • Figure 6-13: Global - Immune Checkpoint Inhibitors Market (Billion US$), 2016-2022
  • Figure 6-14: Global - Yervoy Market (Million US$), 2012-2016
  • Figure 6-15: Global - Opdivo Market (Million US$), 2014-2016
  • Figure 6-16: Global - Keytruda Market (Million US$), 2014-2016
  • Figure 6-17: Global - Others Market (Billion US$), 2016-2022
  • Figure 7-1: Global - Share of Immuno-Oncology Market by Application (%), 2016
  • Figure 7-2: Global - Share of Immuno-Oncology Market by Application (%), 2022
  • Figure 7-3: Global - Head & Neck Cancer Market (Billion US$), 2016-2022
  • Figure 7-4: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-5: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-6: Global - Lung Cancer Market (Billion US$), 2016-2022
  • Figure 7-7: Lung Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-8: Lung Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-9: Global - Melanoma Market (Billion US$), 2016-2022
  • Figure 7-10: Melanoma - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-11: Melanoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-12: Global - Lymphoma Market (Billion US$), 2016-2022
  • Figure 7-13: Lymphoma - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-14: Lymphoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-15: Global - Leukemia Market (Billion US$), 2016-2022
  • Figure 7-16: Leukemia - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-17: Leukemia - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-18: Global - Other Cancer Market (Billion US$), 2016-2022
  • Figure 7-19: Other Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-20: Other Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 8-1: Global - Share of Immuno-Oncology Market by Geographic Regions (%), 2016
  • Figure 8-2: Global - Share of Immuno-Oncology Market by Geographic Regions (%), 2022
  • Figure 8-3: North America - Immuno-Oncology Market (Billion US$), 2016-2022
  • Figure 8-4: Europe - Immuno-Oncology Market (Billion US$), 2016-2022
  • Figure 8-5: Asia-Pacific - Immuno-Oncology Market (Billion US$), 2016-2022
  • Figure 9-1: Immuno-Oncology Funding by Product Type (Billion, US$), 2015-2016
  • Figure 9-2: Major Investors in Immuno-Oncology Market (2015-2016)
  • Figure 9-3: Bristol-Myers Squibb and Merck & Co. - Strategic Collaborations
  • Figure 11-1: Global - Immuno-Oncology Pipeline Analysis by Product Type (%), 2016
  • Figure 11-2: Global - Immuno-Oncology Pipeline Analysis by Phase (%), 2016
  • Figure 12-1: Global - Share of Key Players in Immuno-Oncology Market (%), 2015
  • Figure 13-1: F. Hoffmann-La Roche AG - Sales by Business Segments (%), 2016
  • Figure 13-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Segments (%), 2016
  • Figure 13-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Geography (%), 2016
  • Figure 13-4: Celgene Corporation - Sales by Products (%), 2016
  • Figure 13-5: Bristol Myers Squibb - Revenue by Business Segments (%), 2016
  • Figure 13-6: Bristol Myers Squibb - Revenue by Geography (%), 2016
  • Figure 13-7: Merck & Co., Inc. - Revenue by Business Segments (%), 2016
  • Figure 13-8: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segments (%), 2016
  • Figure 13-9: Merck & Co., Inc. - Revenue by Geography (%), 2016
  • Figure 13-10: Novartis - Sales by Business Segments (%), 2016
  • Figure 13-11: Novartis - Innovative Medicines Division Sales by Segments (%), 2016
  • Figure 13-12: Novartis - Pharmaceuticals Division Sales by Segments (%), 2016
  • Figure 13-13: Novartis - Sales by Geography (%), 2016
  • Figure 13-14: AstraZeneca Plc - Revenue by Business Segments (%), 2016
  • Figure 13-15: AstraZeneca Plc - Revenue by Geography (%), 2016
  • Figure 13-16: Pfizer Inc - Revenue by Business Segments (%), 2016
  • Figure 13-17: Pfizer Inc - Revenue by Geography (%), 2016
  • Figure 13-18: Eli Lilly and Company - Revenue by Business Segments (%), 2016
  • Figure 13-19: Eli Lilly and Company - Human Pharmaceutical Division Revenue by Business Segments (%), 2016
  • Figure 13-20: Eli Lilly and Company - Revenue by Geography (%), 2016
  • Figure 13-21: Johnson & Johnson - Sales by Business Segments (%), 2016
  • Figure 13-22: Johnson & Johnson - Sales by Pharmaceutical Segments (%), 2016
  • Figure 13-23: Johnson & Johnson - Sales by Geography (%), 2016
  • Figure 13-24: Amgen Inc. - Sales by Product (%), 2016
  • Figure 13-25: Amgen Inc. - Sales by Geography (%), 2016

List of Tables:

  • Table 4-1: Immuno-Oncology - Late Stage Research Pipeline
  • Table 4-2: US & Europe - Major Drug Patent Expiry in Immuno-Oncology Market
  • Table 6-1: Ongoing Trials for Rituxan
  • Table 6-2: Ongoing Trials for Avastin
  • Table 6-3: Ongoing Trials for Herceptin
  • Table 6-4: Ongoing Trials for ADCETRIS
  • Table 6-5: Ongoing Trials for Kadcyla
  • Table 6-6: Ongoing Trials for Blincyto
  • Table 6-7: Ongoing Trials for Other Monoclonal Antibodies
  • Table 6-8: Ongoing Trials for Provenge
  • Table 6-9: Ongoing Trials for Yervoy
  • Table 6-10: Ongoing Trials for Opdivo
  • Table 6-11: Ongoing Trials for Keytruda
  • Table 6-12: Ongoing Trials for Other Immuno-Oncology Products
  • Table 7-1: Global - Oncology Incidence by Geography ('000), 2015 & 2020
  • Table 9-1: Immuno-Oncology Companies that Received Venture Capital Investments
  • Table 9-2: Selected Immuno-Oncology and/or Targeted Therapy Combinations
  • Table 10-1: Strategic Collaborations in the Immuno-Oncology Industry
  • Table 11-1: Active Immuno-Oncology Programs
  • Table 11-2: Global - Immuno-Oncology Product Pipeline
  • Table 13-1: F. Hoffmann-La Roche AG - Key Financials (Billion US$), 2014-2016
  • Table 13-2: F. Hoffmann-La Roche AG - Commercialized Immuno-Oncology Products
  • Table 13-3: F. Hoffmann-La Roche AG - Product Pipeline
  • Table 13-4: Celgene Corporation - Key Financials (Million US$), 2014-2016
  • Table 13-5: Celgene Corporation - Commercialized Immuno-Oncology Products
  • Table 13-6: Celgene Corporation - Product Pipeline
  • Table 13-7: Bristol Myers Squibb - Key Financials (Million US$), 2014-2016
  • Table 13-8: Bristol Myers Squibb - Commercialized Immuno-Oncology Products
  • Table 13-9: Bristol Myers Squibb - Product Pipeline
  • Table 13-10: Merck & Co., Inc. - Key Financials (Million US$), 2014-2016
  • Table 13-11: Merck & Co., Inc. - Commercialized Immuno-Oncology Products
  • Table 13-12: Merck & Co., Inc. - Product Pipeline
  • Table 13-13: Novartis - Key Financials (Billion US$), 2014-2016
  • Table 13-14: Novartis - Commercialized Immuno-Oncology Products
  • Table 13-15: Novartis - Product Pipeline
  • Table 13-16: AstraZeneca Plc - Key Financials (Million US$), 2014-2016
  • Table 13-17: AstraZeneca Plc - Commercialized Immuno-Oncology Products
  • Table 13-18: AstraZeneca Plc - Product Pipeline
  • Table 13-19: Pfizer Inc - Key Financials (Billion US$), 2014-2016
  • Table 13-20: Pfizer Inc - Commercialized Immuno-Oncology Products
  • Table 13-21: Pfizer Inc - Product Pipeline
  • Table 13-22: Eli Lilly and Company - Key Financials (Million US$), 2014-2016
  • Table 13-23: Eli Lilly and Company - Commercialized Immuno-Oncology Products
  • Table 13-24: Eli Lilly and Company - Product Pipeline
  • Table 13-25: Johnson & Johnson - Key Financials (Billion US$), 2014-2016
  • Table 13-26: Johnson & Johnson - Commercialized Immuno-Oncology Products
  • Table 13-27: Johnson & Johnson - Product Pipeline
  • Table 13-28: Amgen Inc. - Key Financials (Billion US$), 2014-2016
  • Table 13-29: Amgen Inc. - Commercialized Immuno-Oncology Products
  • Table 13-30: Amgen Inc. - Product Pipeline